Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Investor Presentation (February 2025)
20 slides from Aethlon Medical's investor presentation, February 2025
Slide 1: Corporate Presentation February 2025
Corporate Presentation February 2025 Nasdaq: AEMD wwwˌAethlonMedicalˌcom
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
Slide 3: Misc. Disclaimers
MISC. DISCLAIMERS Market Industry & Data This Presentation discusses trends and markets that Aethlon Medical’s leadership team believes will impact the development and success of Aethlon Medical based on its current understanding of the marketplace. Industry and market data used in this Presentation
Slide 4: Investment Highlights
Investment Highlights • Developing novel, patented Aethlon Hemopurifier® blood purification device • Early clinical trials have demonstrated virus and EV* clearance both in vitro and in patients • Two FDA “Breakthrough Device” designations • The treatment of individuals with advanced or metastatic c
Slide 5: The Aethlon Hemopurifier®
The Aethlon Hemopurifier® FDA Designated “Breakthrough Device” In Viral And Oncology Indications • Safely administered in 165 Hemopurifier sessions in 39 patients1 • Proprietary, patented technology • Has demonstrated clearance of life- threatening viruses • Designed to clear tumor-derived EVs, and
Slide 6: The Hemopurifier's Unique Mechanism of Action Captures Virus and Exosomes from a Patient's Blood
The Hemopurifier®’s Unique Mechanism of Action Captures Virus and Exosomes from a Patient’s Blood via an Extracorporeal Circuit Captures enveloped viral pathogens and exosomes in circulating blood • Hollow-fiber plasma separator filled with proprietary “affinity resin” [Figures B, C] • Size restrict
Slide 7: Pipeline Targeting Multiple Indications
Pipeline Targeting Multiple Indications Early Feasibility Indication Pre-Clinical Study Trial Recruiting in Australia Oncology Solid Tumors Trial being initiated in India failing anti- PD-1 COVID-19 trials Treated two patients and ended Viral Infections in US & India trials due to lack of enrollment
Slide 8: Oncology
a, Oncology
Slide 9: In Vitro and In Vivo Removal Of Cancer-Derived EVs Has Been Demonstrated
In Vitro and In Vivo Removal Of Cancer-Derived EVs Has Been Demonstrated 1 • In vitro: • Experiment #1: Miniature Hemopurifier removed 92-99% of buffer- suspended EVs isolated from multiple tumor types (Marleau AM, Jacobs MT, Gruber N, et al. Cancer Res 2020;80 (16_Supplement):4509.) • Experiment #2
Slide 10: Australian Hemopurifier Oncology Clinical Trial Updates (1)
Australian Hemopurifier Oncology Clinical Trial Updates (1) • Safety, feasibility and “dose finding” clinical trial in patients with stable or progressive malignancies following a 2 month “run-in” period of Pembrolizumab or Nivolumab (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=
Slide 11: Australian Hemopurifier Oncology Clinical Trial Updates (2)
Australian Hemopurifier Oncology Clinical Trial Updates (2) • Suggestions made by clinical investigators to possibly: • Increase patient enrollment • Shorten time to HP treatment • Shorten time to EV and T cell data • Changes include : • Enrolling patients with demonstrated lack of improvement with
Slide 12: Virology
Virology 12
Slide 13: The Aethlon Hemopurifier is Poised as a Potential Countermeasure for Emerging Infections
The Aethlon Hemopurifier® is Poised as a Potential Countermeasure for Emerging Infections Due to Enveloped Viruses • Enveloped viruses contain mannose structures that are the target for the GNA Affinity Resin in the Aethlon Hemopurifier® • Aethlon has amassed a catalogue of in vitro binding data for
Slide 14: In Vitro Data with Aethlon Hemopurifier- H5N1 & Marburg Virus
In Vitro Data with Aethlon Hemopurifier- H5N1 & Marburg Virus In Vitro Removal of H5N1 from Cell Culture Fluid 100% 80% % Remaining 60% TCID50 RNA 40% 20% 0% 0 4 8 Time (hrs)12 16 20 Up to 99% removal after 6 hours- Internal Data –Battelle 50-70% reduction in Marburg virus in 3 hours- Koch et Memori
Slide 15: Emergency Use Patient: Demonstrated In Vivo Viral Load Reduction in Ebola Patient (Germany)
Emergency Use Patient: Demonstrated In Vivo Viral Load Reduction in Ebola Patient (Germany) 38-year-old Uganda male admitted to Frankfurt Hospital with fevers chills, abdominal pain, emesis and diarrhea Patient Viral Load Measurements • 10/3/14: viral load 1.84x 108 copies/ml 4.0E+05 • 10/08/14 (EVD
Slide 16: Long COVID pre-clinical research
Long COVID pre-clinical research • Long COVID is the persistence of symptoms at least 3 months following acute infection with the SARS-CoV-2 virus • CDC estimated point prevalence of Long COVID to be between 6-7% in the general population (https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm) • Glo
Slide 17: Aethlon's patent portfolio provides protection until as early as 2025
Aethlon’s patent portfolio provides protection until as early as 2025 (issued patents) and as late as 2044 (if pending applications are granted) United States International • Issued Patents: • Issued Patents: • 3 US patents issued covering extracorporeal removal of • 24 foreign patents covering exos
Slide 18: Senior Management Team Has Extensive Experience With Both Medical Devices And Therapeutics
Senior Management Team Has Extensive Experience With Both Medical Devices And Therapeutics James B. Frakes, MBA, Chief Executive Officer & Chief Financial Officer • Over 30 years public company CFO experience • Investment banking & venture capital Steven P. LaRosa, MD, Chief Medical Officer • 26 yea
Slide 19: Key Financial Highlights
Key Financial Highlights • Approximately $4.8 million in cash as of December 31, 2024 • No debt on balance sheet • Approximately 14.5 million shares outstanding as of February 10, 2025 • Market capitalization of $9.4 million as of February 10, 2024 • Trading on Nasdaq Capital Market under the ticker
Slide 20: Contact Information
Contact Information 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD AethlonMedical.com This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including: whether and when our products
Aethlon Medical — Investor Presentation (February 2025) on 6ix